Hill January 11, 2024
Despite receiving reports of patients experiencing suicidal ideation last year, the Food and Drug Administration (FDA) said it has not found a link between this side effect and the class of diabetes drugs that includes Ozempic, Mounjaro and Zepbound.
The FDA received reports in 2023 of patients experiencing suicidal ideation, hair loss and aspiration — an obstruction of the airway — after taking GLP-1 agonists, a category of drugs that treats diabetes and obesity by mimicking a naturally-occurring hormone.
These side effects were not listed on the medication guides for popular GLP-1 agonists, leading the FDA to open an inquiry into whether further regulation was needed for these types of drugs.
“Our preliminary evaluation has not found evidence that use...
Today's Sponsors
Today's Sponsor